Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 294-314 , October 2006

Platelet Immunopathology and Therapy: A Canadian Blood Services Research and Development Symposium

References 

  1. Coopamah MD, Garvey MB, Freedman J, et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: An update. Transfus. Med. Rev. 2003;17:69–80
  2. Janeway CA, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002;20:197–216
  3. Watts C:. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu. Rev. Immunol. 1997;15:821–850
  4. Chambers CA. The expanding world of co-stimulation: The two-signal model revisited. Trends. Immunol. 2001;22:217–223
  5. Elson CJ, Barker RN. Helper T cells in antibody-mediated, organ-specific autoimmunity. Curr. Opin. Immunol. 2000;12:664–669
  6. Mosmann TR, Sad D. The expanding universe of T-cell subsets: Th1 Th2 and more. Immunol. Today. 1996;17:138–146
  7. Maloy KJ, Powie F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001;2:816–822
  8. Coutinho A, Haas W. In vivo models of dominant T-cell tolerance: Where do we stand today?. Trends. Immunol. 2001;22:350–351
  9. Mackay IR. The “autoimmune diseases” 40th anniversary. Autoimmun. Rev. 2002;1:5–11
  10. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends. Immunol. 2001;22:443–449
  11. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94:909–913
  12. Blanchette VS, Semple JW, Freedman J. Intravenous immunoglobulin and Rh immunoglobulin as immunomodulators of autoimmunity to blood elements. In:  Silberstein LE editors. Autoimmune disorders of blood. Bethesda (Md): American Association of Blood Banks; 1996;p. 35–77
  13. Wright JF, Blanchette VS, Wang H, et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br. J. Haematol. 1996;95:145–152
  14. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin. Hematol. 2000;37:239–248
  15. Semple JW, Freedman J. Enhanced anti-platelet lymphocyte reactivity in patients with autoimmune thrombocytopenia (AITP). Blood. 1991;78:2619–2625
  16. Filion MC, Bradley AJ, Devine DV, et al. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur. J. Immunol. 1995;25:3123–3127
  17. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: An update. Transfus. Sci. 1998;19:245–251
  18. Kuwana M, Kaburaki J, Kitasato H, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98:130–139
  19. Semple JW, Speck ER, Kim M, et al. Characterization and fine specificity of platelet-reactive T cell lines from children with chronic autoimmune thrombocytopenic purpura (AITP). Blood. 2001;98:440a;(abstr, suppl 1)
  20. Yssel H, de Vries J, de Waal Malefyt R. IL-10 is produced by subsets of human CD4+ T cell clones and peripheral blood T cells. J. Immunol. 1992;149:2378–2384
  21. Garcia-Suarez J, Prieto A, Reyes E, et al. Abnormal γIFN and TNFα secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura patients: Their implication in the clinical course of the disease. Am. J. Hematol. 1995;49:271–276
  22. Abboud MR, Laver J, Xu F, et al. Serum levels of GM-CSF are elevated in patients with thrombocytopenia. Br. J. Haematol. 1996;92:486–488
  23. Lazarus AH, Ellis J, Semple JW, et al. Comparison of platelet immunity in patients with SLE and ITP. Transfus. Sci. 2000;22:19–27
  24. Mouzaki A, Theodoropoulou M, Gianakopoulos I, et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: Their role in prognosis. Blood. 2002;100:1774–1779
  25. Andersson PO, Stockelberg D, Jacobsson S, et al. A transforming growth factor-beta 1–mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura. Ann. Hematol. 2000;79:507–513
  26. Karakantza M, Mouzaki A, Theodoropoulos M, et al. Th1 and Th2 cytokines in a patient with Evan's syndrome and profound lymphopenia. Br. J. Haematol. 2000;110:968–970
  27. Lazarus AH, Joy T, Crow AR. Analysis of transmembrane signaling and T cell defects associated with idiopathic thrombocytopenic purpura (ITP). Acta. Paediatr. Suppl. 1998;424:21–25
  28. Aiura K, Clark BD, Dinarello CA, et al. Interaction with autologous platelets multiplies interleukin-1 and tumor necrosis factor production in mononuclear cells. J. Infect. Dis. 1997;175:123–129
  29. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated IL-1β synthesis. J. Cell. Biol. 2001;154:485–490
  30. Olsson B, Andersson PO, Jernas M, et al. T-cell–mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 2003;9:1123–1124
  31. Kroll H, Yates J, Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: Characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion. 2005;45:353–358
  32. Ertel K, Al-Tawil M, Santoso S, et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion. 2005;45:366–373
  33. Peterson JA, Balthazor SM, Curtis BR, et al. Maternal alloimmunization against the rare platelet-specific antigen HPA-9b (Maxa) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion. 2005;45:1487–1495
  34. Beiboer SH, Wieringa-Jelsma T, Maaskant-Van Wijk PA, et al. Rapid genotyping of blood group antigens by multiplex polymerase chain reaction and DNA microarray hybridization. Transfusion. 2005;45:667–679
  35. Bugert P, McBride S, Smith G, et al. Microarray-based genotyping for blood groups: Comparison of gene array and 5′-nuclease assay techniques with human platelet antigen as a model. Transfusion. 2005;45:654–659
  36. Denomme GA, Van Oene M. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion. 2005;45:660–666
  37. Carl B, Kroll H, Bux J, et al. B-lymphoblastoid cell lines as a source of reference DNA for human platelet and neutrophil antigen genotyping. Transfusion. 2000;40:62–68
  38. Griffin HM, Ouwehand WH. A human monoclonal antibody specific for the leucine-33 (P1A1, HPA-1a) form of platelet glycoprotein IIIa from a V gene phage display library. Blood. 1995;86:4430–4436
  39. Proulx C, Chartrand P, Roy V, et al. Human monoclonal Fab fragments recovered from a combinatorial library bind specifically to the platelet HPA-1a alloantigen on glycoprotein IIb-IIIa. Vox Sang. 1997;72:52–60
  40. Garner SF, Smethurst PA, Merieux Y, et al. A rapid one-stage whole-blood HPA-1a phenotyping assay using a recombinant monoclonal IgG1 anti–HPA-1a. Br. J. Haematol. 2000;108:440–447
  41. Taaning F. HLA antibodies and fetomaternal alloimmune thrombocytopenia: Myth or meaningful?. Transfus. Med. Rev. 2000;14:275–280
  42. Harrison CR, Curtis BR, McFarland JG, et al. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion. 2003;43:1398–1402
  43. Santoso S, Kalb R, Walka M, et al. The human platelet alloantigens Br(a) and Br(b) are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit alpha 2). J. Clin. Invest. 1993;92:2427–2432
  44. Bowditch RD, Tani PH, Halloran CE, et al. Localization of a PlA1 epitope to the amino terminal 66 residues of platelet glycoprotein IIIa. Blood. 1992;79:559–562
  45. Barron-Casella EA, Kickler TS, Rogers OC, et al. Expression and purification of functional recombinant epitopes for the platelet antigens, PlA1 and PlA2. Blood. 1994;84:1157–1163
  46. Barron-Casella EA, Nebbia G, Rogers OC, et al. Construction of a human platelet alloantigen-1a epitope(s) within murine glycoprotein IIIa: Identification of residues critical to the conformation of the antibody binding site(s). Blood. 1999;93:2959–2967
  47. Honda S, Honda Y, Bauer B, et al. The impact of three-dimensional structure on the expression of PlA alloantigens on human integrin beta 3. Blood. 1995;86:234–242
  48. Valentin N, Visentin GP, Newman PJ. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: Evidence for heterogeneity in the humoral response. Blood. 1995;85:3028–3033
  49. Liu LX, Nardi MA, Casella JF, et al. Inhibition of binding of anti-PLA1 antibodies to platelets with monoclonal antibody LK-4. Evidence for multiple PLA1 receptor sites on platelet GPIIIa. Blood. 1996;88:3601–3607
  50. Watkins NA, Schaffner-Reckinger E, Allen DL, et al. HPA-1a phenotype-genotype discrepancy reveals a naturally occurring Arg93Gln substitution in the platelet beta 3 integrin that disrupts the HPA-1a epitope. Blood. 2002;9:1833–1839
  51. Santoso S, Kroll H, Andrei-Selmer C, et al. A naturally occurring Leu33Val mutation in β3 integrin impairs the HPA-1a epitope: The third allele of HPA-1. Transfusion. 2006;46:790–799
  52. Kroll H, Penke G, Santoso S. Functional heterogeneity of alloantibodies against the human platelet antigen (HPA)–1a. Thromb. Haemost. 2005;94:1224–1229
  53. Aster RH. Drug-induced immune cytopenias. Toxicology. 2005;209:149–153
  54. Aljitawi OS, Krishnan K, Curtis BR, et al. Serologically documented loracarbef (Lorabid)–induced immune thrombocytopenia. Am. J. Hematol. 2003;73:41–43
  55. Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood. 1994;84:176–183
  56. Bougie D, Aster R. Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen. Blood. 2001;97:3846–3850
  57. Kroll H, Sun QH, Santoso S. Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a target glycoprotein in drug-induced thrombocytopenia. Blood. 2000;96:1409–1414
  58. Peterson JA, Nyree CE, Newman PJ, et al. A site involving the “hybrid” and PSI homology domains of GPIIIa (beta 3-integrin subunit) is a common target for antibodies associated with quinine-induced immune thrombocytopenia. Blood. 2003;101:937–942
  59. Asvadi P, Ahmadi Z, Chong BH. Drug-induced thrombocytopenia: Localization of the binding site of GPIX-specific quinine-dependent antibodies. Blood. 2003;102:1670–1677
  60. Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood. 1998;92:2359–2365
  61. Burgess JK, Lopez JA, Gaudry LE, et al. Rifampicin-dependent antibodies bind a similar or identical epitope to glycoprotein IX–specific quinine-dependent antibodies. Blood. 2000;95:1988–1992
  62. Yeghiazarians Y, Braunstein JB, Askari A, et al. Unstable angina pectoris. N. Engl. J. Med. 2000;342:101–114
  63. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood. 2002;100:2071–2076
  64. Aster RH, Curtis BR, Bougie DW. Thrmobocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors. Semin. Thromb. Hemost. 2004;30:569–577
  65. Curtis BR, Swyers J, Divgi A, et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002;99:2054–2059
  66. Curtis BR, Blank J, Marques MB, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am. J. Hematol. 2006;81:193–198
  67. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin. Hematol. 1998;35:9–16(Suppl 5)
  68. Warkentin TE. Management of heparin-induced thrombocytopenia: A critical comparison of lepirudin and argatroban. Thromb. Res. 2003;110:73–82
  69. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 1992;68:95–96
  70. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood. 1994;84:3691–3699
  71. Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 1997;127:804–812
  72. Pouplard C, Iochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97:3300–3302
  73. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin. Thromb. Hemost. 2004;30:273–283
  74. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 1995;332:1330–1335
  75. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106:3791–3792
  76. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood. 2005;106:2710–2715
  77. Warkentin TE, Sheppard JI, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia. How much class do we need?. J. Lab. Clin. Med. 2005;146:341–346
  78. Alberio L, Kimmerle S, Baumann A, et al. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am. J. Med. 2003;114:528–536
  79. Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J. Thromb. Haemost. 2006;4:759–765
  80. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus. Thromb. Haemost. 1998;79:1–7
  81. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:311S–337S(3 Suppl)
  82. Slichter S, Harker L. Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin. Hematol. 1978;7:523–529
  83. Hanson S, Slichter S. Platelet kinetics in patients with bone marrow hypoplasia: Evidence for a fixed platelet requirement. Blood. 1985;66:1105–1109
  84. Gaydos L, Freireich N, Mantel E. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N. Engl. J. Med. 1962;266:905–909
  85. Slichter S, LeBlanc R, Jones M, et al. Quantitative analysis of bleeding risk in cancer patients prophylactically transfused at platelet counts of 5,000, 10,000 or 20,000 platelets/μL. Blood. 1999;94:376a;(suppl, abstr)
  86. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N. Engl. J. Med. 1997;337:1870–1875
  87. Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J. Clin. Oncol. 1997;15:1143–1149
  88. Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 × 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 × 10(9)/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukemia. Blood. 1998;91:3601–3606
  89. Zumberg MS, del Rosario ML, Nejame CF, et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. Biol. Blood Marrow Transplant. 2002;8:569–576
  90. Gil-Fernandez JJ, Alegre A, Fernandez-Villalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant. 1996;18:931–935
  91. Lawrence JB, Yomtovian R, Hammons T. Lowering the prophylactic platelet transfusion threshold: A prospective analysis. Leuk. Lymphoma. 2002;41:67–76
  92. Navarro JT, Hernandez JA, Ribera JM. Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/μL versus 20,000/μL. Haematologica. 1998;83:998–1000
  93. Kuter D, Rosenberg R. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelets mass during Busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720–2730
  94. Möller P, Andersson P, Andersson A, et al. Plasma thrombopoietin concentrations in response to platelet transfusion therapy. Acta Haematol. 2000;102:131–134
  95. Debili N, Wendling F, Cosman D, et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood. 1995;85:391–401
  96. Norol F, Bierling P, Roudot-Thoraval F, et al. Platelet transfusion: A dose-response study. Blood. 1998;92:1448–1453
  97. Hersh JK, Hom EG, Brecher ME. Mathematical modeling of platelet survival with implications for optimal transfusion practice in the chronically platelet transfusion–dependent patient. Transfusion. 1998;38:637–644
  98. Murphy S. Radiolabeling of PLTs to assess viability: A proposal for a standard. Transfusion. 2004;44:131–133
  99. Sullivan MT, Wallace EL. Blood collection and transfusion in the United States in 1999. Transfusion. 2005;45:141–148
  100. British Committee for Standards in BTTF . Haematology, Guidelines for the use of platelet transfusions. Br. J. Haematol. 2003;122:10–23
  101. Brubaker DB, Marcus C, Holmes E. Intravascular and total body platelet equilibrium in healthy volunteers and in thrombocytopenic patients transfused with single donor platelets. Am. J. Hematol. 1998;58:165–176
  102. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N. Engl. J. Med. 1997;337:1861–1869
  103. Peter-Salonen K, Bucher U, Nydegger UE. Comparison of posttransfusion recoveries achieved with either fresh or stored platelet concentrates. Blut. 1987;54:207–212
  104. Norol F, Kuentz M, Cordonnier C, et al. Influence of clinical status on the efficiency of stored platelet transfusion. Br. J. Haematol. 1994;86:125–129
  105. Heal JM, Rowe JM, McMican A, et al. The role of ABO matching in platelet transfusion. Eur. J. Haematol. 1993;50:110–117
  106. Friedberg RC, Donnelly SF, Boyd JC, et al. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood. 1993;81:3428–3434
  107. Ogasawara K, Ueki J, Takenaka M, et al. Study on the expression of ABH antigens on platelets. Blood. 1993;82:993–999
  108. Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446–1456
  109. Bolgiano DC, Larson EB, Slichter SJ. A model to determine required pool size for HLA-typed community donor apheresis programs. Transfusion. 1989;29:306–310
  110. Bussel JB. Alloimmune thrombocytopenia in the fetus and newborn. Semin. Thromb. Hemost. 2001;27:245–252
  111. Johnson JA, Ryan G, al Musa A, et al. Prenatal diagnosis and management of neonatal alloimmune thrombocytopenia. Semin. Perinatol. 1997;21:45–52
  112. Poon MC, d'Oiron R, Von Depka M, et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: Results of an international survey. J. Thromb. Haemost. 2004;2:1096–1103
  113. Poon MC, Demers C, Jobin F, et al. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951–3953
  114. Lisman T, Moschatsis S, Adelmeijer J, et al. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor–independent thrombin generation. Blood. 2003;101:1864–1870
  115. Galan AM, Tonda R, Pino M, et al. Increased local procoagulant action: A mechanism contributing to the favorable hemostatic effect of recombinant FVIIa in PLT disorders. Transfusion. 2003;43:885–892
  116. Soslau G, Class R, Morgan DA, et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J. Biol. Chem. 2001;276:21173–21183
  117. Brecher ME, Moore SB, Letendre L. Posttransfusion purpura: The therapeutic value of PlA1-negative platelets. Transfusion. 1990;30:433–435
  118. Loren AW, Abrams CS. Efficacy of HPA-1a (PlA1)–negative platelets in a patient with post-transfusion purpura. Am. J. Hematol. 2004;76:258–262
  119. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rho(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood. 2005;106:1532–1537

 This conference, the Third Annual Canadian Blood Services Research And Development International Symposium took place at the University of Toronto in Toronto, Ontario, Canada, on September 10, 2005, and was chaired by Dr Donald R. Branch, Research and Development Scientist, Canadian Blood Services, and Associate Professor of Medicine, University of Toronto.

PII: S0887-7963(06)00033-2

doi: 10.1016/j.tmrv.2006.05.008

Transfusion Medicine Reviews
Volume 20, Issue 4 , Pages 294-314 , October 2006

Article Tools

* Image Usage & Resolution